Delivery Order SPE2DB25D9321-SPE2DB25FQWPR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- The Defense Logistics Agency issued a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count packaging. This delivery order was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, utilizing firm fixed-price pricing with no set-aside designation. The order represents a discrete fulfillment under DMS...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units) with a ceiling value of $3,458.51. The contract was awarded on September 9, 2025, with an ultimate completion date of September 30, 2025, utilizing firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $10,375.53 for 30 Nuplazid 34 mg capsules by the Defense Logistics Agency's Medical Supply Chain on August 7, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a continuation of pharmaceutical supply services to the Department of Defense healthcare system. The contract carries...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $10,093.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has an ultimate completion date of December 9, 2024, is for the delivery of Nuplazid 34 mg capsules. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count units. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,364.50, covers the supply of the drug Nuplazid 34 mg capsules with a completion date of July 22, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules (30-count units). This firm fixed-price delivery order, issued on August 7, 2025, with completion targeted for August 28, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,093.50 contract is for the supply of Nuplazid 34 mg capsules with a performance period through May 28, 2024. This delivery order is placed under DMS Pharmaceutical Group's $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue firm...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 20, 2025. The contract covers the supply of Nuplazid 34 mg capsules in quantities of 30, with a firm fixed-price structure and an ultimate completion date of September 11, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete on an...
- SPE2DB25D9321Indefinite Delivery Contract
- SPE2DB25D9321-SPE2DB25FQWPRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. on September 10, 2025, for the supply of Nuplazid 34 mg capsules (30-count packaging). This firm fixed-price delivery order, which has an ultimate completion date of October 1, 2025, represents a tactical pharmaceutical procurement executed under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, allowing the vendor to compete on an unrestricted basis despite its status as a woman-owned small business. Performance of the order will be fulfilled from the vendor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, holding a significant single-award IDC with DLA valued at approximately $500 million through November 2026. This master contract enables the issuance of delivery orders for a comprehensive portfolio of pharmaceutical products supporting Department of Defense healthcare facilities worldwide. The vendor's consistent track record of supplying specialty medications—including oncology treatments, biologics, vaccines, and prescription drugs—to military health systems positions it as an established and reliable partner for federal pharmaceutical distribution requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/10/25 |